TRVN trevena.com: Enterprise Value to EBITDA Ratio
Trevena, Inc. (TRVN) is establishing strategic partnerships with outpatient centers and hospitals to integrate its developments into clinical practice. The company is creating opioid alternatives, targeting anesthesiologists and US inpatient facilities with its drug Olinvyk. Currently, the business is optimizing resources and focusing on targeted molecular research. This chart of the share price on GURU.Markets shows that the EV/EBITDA is .
Metric breakdowns and analytics for trevena.com (TRVN)
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- business debt structure and liquidity details:
- financial results and valuation multiples details:
TRVN - Net Income|Future Profit Trevena, Inc.|TRVN - Business Payback Period|Projected Price to Earnings Trevena, Inc.|TRVN - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Trevena Inc|TRVN - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Trevena|TRVN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months trevena.com|TRVN - Earnings per share growth this year|Net earnings per share growth forecast for next year Trevena, Inc.
Summary company analysis:Trevena, Inc TRVN
Trevena, Inc. specializes in developing innovative analgesics and CNS therapies, which requires significant capital expenditures. The EV/EBITDA metric compares the enterprise value, including net debt, with operating profit, excluding the impact of taxes and depreciation. The current value of allows an investor to assess the fundamental value of assets by analyzing the EV/EBITDA valuation level for signs of being overbought or the risk of default.
Analysis of competing companies
EV/EBITDA Multiple BIIB (Biogen Corp)|Neurocrine Corp (NBIX) - Company Value to EBITDA|RGC: Enterprise Value to EBITDA Ratio|AXSM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACAD: EV/EBITDA Multiple|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus Corp)|EV/EBITDA Multiple CPRX|EV/EBITDA Multiple denalitherapeutics.com (DNLI)|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Trevi Corp TRVI|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AVXL|CBLL (CeriBell) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Prothena Corporation PLC (PRTA)|Enterprise Value to EBITDA Ratio ALEC (Alector, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Annexon Biosciences Inc.|Omeros - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio NGNE (neurogene.com)|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VYGR (Voyager Therapeutics Inc)|NMRA (Neumora Therapeutics Inc) - Enterprise Value to EBITDA Ratio|SCLX (Scilex Holding Company, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tevogen Bio Holdings|Enterprise Value to Operating Income Before Depreciation ACOG (Alpha Cognition Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cognition Therapeutics, Inc. (CGTX)|Inhibikase Therapeutics Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAVA (Cassava)|Assertio Holdings (ASRT) - Company Value to EBITDA|COYA: Enterprise Value to EBITDA Ratio|VTGN - EV/EBITDA Multiple|ovidrx.com (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Acumen Pharmaceuticals Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Company Value to EBITDA Alterity Therapeutics Ltd ATHE|Enterprise Value to EBITDA Ratio CLNN (Clene Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio PEPG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Business Value to Operating Income Before Depreciation RLMD|Annovis Bio Corp - EV/EBITDA Multiple|Company Value to EBITDA Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience, Inc) - Enterprise Value to EBITDA Ratio|KLTO (Klotho Neurosciences) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NRSN (NeuroSense Therapeutics Ltd) - EV/EBITDA Multiple|Company Value to EBITDA Reviva Pharmaceuticals Holdings Inc. RVPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia Inc (MTVA)|NeurAxis Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple HSDT (Helius Medical Technologies)|EV/EBITDA Multiple Passage Bio Inc. PASG|NEUP: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation NERV (Minerva Neurosciences Inc)|ATHA: EV/EBITDA Multiple|ADXN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alzamend Neuro Inc.|Enterprise Value to Operating Income Before Depreciation CYCN (Cyclerion)|EV/EBITDA Multiple PTIX|Enterprise Value to EBITDA Ratio pasitheaclinics.com KTTA|Cortigent - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Avenue Therapeutics Inc (ATXI)|BCLI: Enterprise Value to EBITDA Ratio|caratherapeutics.com - Enterprise Value to Operating Income Before Depreciation Ratio|Chromocell Therapeutics Corp. (CHRO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Eliem Therapeutics Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LBPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Marinus Pharmaceuticals (MRNS)|nkgenbiotech.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroBo Pharmaceuticals, Inc. NRBO|SAGE: Enterprise Value to Operating Income Before Depreciation|Neurotrope - EV/EBITDA Multiple|Company Value to EBITDA Vigil Neuroscience|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|cerevel.com (CERE) - EV/EBITDA Multiple
